DUBLIN--(http://www.researchandmarkets.com/research/jttsn9/biopharmaceutical) has announced the addition of the "BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges" report to their offering.)--Research and Markets (
“BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges”
The Chinese Pharmaceutical market is currently the third greatest pharma market globally, after the US and Japan, and in 2011 was worth $40 billion. It is forecast to increase dramatically by 2015 and increase its dominance as a leading player in Asia. As the current third market leader it is predicted that the Chinese pharma market will be the main competitor of the US by 2020.
This report describes the current therapeutics that are propelling the biopharmaceutical market in China. It examines the current economic climate and how China compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Chinese pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in China. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
In summary, the Chinese biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment.
This report tackles key concerns to the Chinese biopharmaceutical market such as:
- Lack of regulatory policy and legislation
- Reimbursement schemes and payers concerns
- Funding and government sponsorship issues
- International scepticism of Chinese safety and efficacy therapeutic profiles
- Abbottt China
- AstraZeneca China
- AstraZeneca Products in China
- Boehringer Ingelheim China
- Eli Lilly China
- GlaxoSmithKline China
- Johnson & Johnson Medical China
- Merck China
- Novartis China
- Pfizer China
- Roche China
- Amoytop Biotech
- FusoGen Pharmaceuticals
- Shanghai Huaguan Biochip
- SiBiono GeneTech
- Sinovac Biotech
For more information visit http://www.researchandmarkets.com/research/jttsn9/biopharmaceutical